Methadone Therapy - One Dose Does Not Fit All
Study supports a flexible approach to methadone dosing
Methadone has been used for more than 30 years as a treatment for heroin addicts. Doctors have all along struggled to find the best doses to help patients overcome their heroin cravings without getting them used to higher levels of methadone (itself an dependence-forming substance) than necessary. A new study by Jodie Trafton and colleagues (from the VA Palo Alto Health Care System) provides strong support for the notion that there is no one dose that fits all.
Current guidelines recommend methadone doses of at least 60 milligrams (per kilogram bodyweight). However, doctors in methadone clinics report a wide range of doses that are effective, and quite a few clinics treat patients with starting doses that are lower or higher than the recommended amount. Trafton and colleagues studied 222 heroin addicted volunteers who started methadone treatment at 8 different clinics and followed them for up to a year. They examined the range of methadone doses which helped patients achieve heroin abstinence and the factors that influenced whether a particular patient needed a higher or a lower dose.
The range of effective methadone doses (among the 168 patients who achieved abstinence) was very wide, from 1.5 mg to 191.2 mg. 38% of the patients achieved abstinence on less than 60 mg, and 16% of the abstinent patients received a dose of over 100 mg. On the other hand, almost half of the patients who did not achieve heroin abstinence received the recommended dose of 60 mg or more. Overall, patients at clinics that generally adhered to the treatment guidelines (and treated most patients at 60mg or higher) achieved longer periods of abstinence. Among patients who achieved abstinence, higher methadone doses were correlated with post-traumatic stress disorder, depression, a higher number of previous detoxifications from heroin, and some other factors.
These results confirm that effective methadone doses vary very widely. Even high doses that work for one patient do not necessarily work for another, and a substantial percentage of patients achieve abstinence on less than the recommended dose. The study also identifies some factors, such as post-traumatic stress disorder and depression, that seem to influence whether a patient is more likely to need a higher dose. The authors conclude that doctors should work with each patient to find the lowest effective dose for that individual. Because patients in clinics that adhere to the guidelines do better on average, the recommended dose should serve as a starting point that is then adjusted upward or downward.
Andrew Hyde | alfa
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
New success for Konstanz physicists in studying the quantum vacuum
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...